- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches Q1 2012
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
April 04, 2012
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) | Indication | Launch Date |
---|---|---|---|---|---|
Yaz | Bayer HealthCare Pharmaceuticals Inc.'s | Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol) | Watson Pharmaceuticals | prevention of pregnancy and for the treatment of moderate acne in women | Jan. 18, 2012 |
Zanaflex | Watson Pharmaceuticals | tizanidine hydrochloride capsules | Acorda Therapeutics, | short-acting drug indicated for the management of spasticity. | Feb. 6, 2012 |
Zanaflex | Acorda Therapeutics | tizanidinehydrochloride | Apotex | Multiple sclerosis skeletal muscle relaxants | Feb. 9, 2012 |
Lexapro | Forest Laboratory | Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg | Mylan Pharmaceuticals Inc. | depression and generalized anxiety disorder treatment | Feb. 29, 2012 |
Geodon | Pfizer Inc.'s | ziprasidone | Dr. Reddy's Laboratories | antipsychotic drug | Mar. 2, 2012 |
Prometrium | Abbott Laboratories | Progesterone Capsules, 100 & 200 mg | Teva Pharmaceutical Industries Ltd. | secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus. | Mar. 2, 2012 |
Prometrium | Abbott Laboratories | Progesterone Capsules, 100 & 200 mg | Watson Pharmaceuticals | secondary amenorrhea due to a decrease in progesterone as well as in conjunction with estrogen-containing medications in postmenopausal women with a uterus. | Mar. 2, 2012 |
Geodon | Pfizer Inc.'s | ziprasidone | Lupin Pharmaceuticals | antipsychotic drug | Mar. 3, 2012 |
Lexapro | Forest Laboratory | Escitalopram Oxalate Tablets | Teva Pharmaceutical Industries Ltd. | depression and generalized anxiety disorder treatment | Mar. 14, 2012 |
Lexapro | Forest Laboratory | Escitalopram Oxalate Tablets | Amneal Pharmaceuticals | depression and generalized anxiety disorder treatment | Mar. 15, 2012 |
Seroquel | AstraZeneca | quetiapine fumarate tablets | Teva Pharmaceutical Industries Ltd. | antidepressants in major depressive disorder and acute depressive episodes in bipolar disorder | Mar. 28, 2012 |
Seroquel | AstraZeneca | quetiapine fumarate tablets | Mylan Pharmaceuticals Inc. | antidepressants in major depressive disorder and acute depressive episodes in bipolar disorder | Mar. 28, 2012 |
GENERICally Speaking Spring 2012
Related Publications
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
March 25, 2024
Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2024
Mallinckrodt plc v. Airgas Therapeutics LLC
GENERICally Speaking Hatch Waxman Bulletin
March 8, 2024
UCB, Inc. v. Mylan Techs. Inc.
GENERICally Speaking Hatch Waxman Bulletin
March 5, 2024
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.